Introduction
Methods
Data source
Study population and design
Classification of psychotropic drugs
-
SSRIs: escitalopram, citalopram, sertraline*
-
Selective serotonin-norepinephrine reuptake inhibitors (SSNRIs): venlafaxine, duloxetine*
-
TCAs: trimipramine, amitriptyline, doxepin*
-
Noradrenergic and specific serotonergic antidepressants (NaSSAs): mirtazapine*
-
Monoamine oxidase inhibitors (MAOIs): tranylcypromine, moclobemide**
-
Other ADDs: trazodone, bupropion, agomelatine*
-
lp FGAs: pipamperone, promethazine, prothipendyl, melperone*
-
hp FGAs: haloperidol, perazine, flupentixol**
-
SGAs: quetiapine, olanzapine, risperidone, aripiprazole*
Statistical analysis
Results
Sociodemographic and illness-related data according to sex
M | F | RR (95% CI) | |||
---|---|---|---|---|---|
N | (%) | N | (%) | ||
Total | 16,547 | 37.3 | 27,871 | 62.7 | |
Age in years (mean) | 48.81 | 51.53 | |||
Age groups | |||||
< 31 | 2466 | 14.9 | 3585 | 12.9 | 1.15 (1.10–1.22) |
31–60 | 10,396 | 62.8 | 16,019 | 57.5 | 1.09 (1.08–1.11) |
61–90 | 3661 | 22.1 | 8197 | 29.4 | 0.75 (0.73–0.78) |
> 91 | 24 | 0.1 | 70 | 0.3 | 0.58 (0.36–0.92) |
Diagnosis | |||||
Mild depression | 236 | 1.4 | 314 | 1.1 | 1.27 (1.07–1.50) |
Moderate depression | 4543 | 27.5 | 7773 | 27.9 | 0.98 (0.95–1.02) |
Severe depression | 9636 | 58.2 | 16,326 | 58.6 | 0.99 (0.98–1.01) |
Severe depression with psychosis | 2132 | 12.9 | 3458 | 12.4 | 1.04 (0.99–1.09) |
Pat. receiving any psychotropic drugs | 15,764 | 95.3 | 26,799 | 96.2 | 0.99 (0.99–0.99) |
N psychotropic drugs (mean) | 2.60 | 2.68 | |||
N psychotropic drugs | |||||
0 | 783 | 4.7 | 1072 | 3.8 | 1.23 (1.12–1.35) |
1 | 3553 | 21.5 | 5527 | 19.8 | 1.08 (1.04–1.12) |
2 | 4923 | 29.8 | 8246 | 29.6 | 1.00 (0.98–1.03) |
3 | 3847 | 23.2 | 6690 | 24.0 | 0.97 (0.94–1.00) |
4 + | 3441 | 20.8 | 6336 | 22.7 | 0.91 (0.88–0.95) |
Prescription trends of psychotropic drugs according to sex
Antidepressant drugs
2001–2017 | 2001–2003 | 2015–2017 | Sex differences over time | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | M vs. F | M | F | M vs. F | M | F | M vs. F | 2001–2003 vs. 2015–2017 | |||||||
N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | RRR (95% C1) | |
N patients | 16,547 | 27,871 | 1527 | 2863 | 3936 | 6304 | ||||||||||
ADD | ||||||||||||||||
Any ADD | 14,431 | 87.2 | 24,794 | 89.0 | 0.98 (0.94–1.00) | 1361 | 89.1 | 2578 | 90.0 | 0.99 (0.97–1.01) | 3311 | 84.1 | 5445 | 86.4 | 0.97 (0.96–0.99) | 0.98 (0.96–1.01) |
SSRI | 5154 | 31.1 | 9208 | 33.0 | 0.94 (0.92–0.97) | 508 | 33.3 | 898 | 31.4 | 1.06 (0.97–1.16) | 1199 | 30.5 | 2103 | 33.4 | 0.91 (0.86–0.97) | 0.86 (0.77–0.96) |
Escitalopram | 1642 | 9.9 | 2913 | 10.5 | 0.95 (0.90–1.00) | 54 | 3.5 | 81 | 2.8 | 1.25 (0.89–1.75) | 369 | 9.4 | 753 | 11.9 | 0.78 (0.70–0.88) | 0.63 (0.44–0.90) |
Citalopram | 1477 | 8.9 | 2684 | 9.6 | 0.93 (0.87–0.98) | 210 | 13.8 | 400 | 14.0 | 0.98 (0.84–1.15) | 194 | 4.9 | 317 | 5.0 | 0.98 (0.82–1.17) | 1.00 (0.79–1.26) |
Sertraline | 1478 | 8.9 | 2356 | 8.5 | 1.06 (0.99–1.12) | 124 | 8.1 | 229 | 8.0 | 1.02 (0.82–1.25) | 570 | 14.5 | 823 | 13.1 | 1.11 (1.00–1.22) | 1.09 (0.87–1.38) |
SSNRI | 4689 | 28.3 | 8323 | 29.9 | 0.95 (0.92–0.98) | 277 | 18.1 | 494 | 17.3 | 0.98 (0.84–1.15) | 1150 | 29.2 | 1947 | 30.9 | 0.95 (0.89–1.01) | 0.90 (0.78–1.04) |
Venlafaxine | 3343 | 20.2 | 5737 | 20.6 | 0.98 (0.94–1.02) | 275 | 18.0 | 486 | 17.0 | 1.06 (0.93–1.21) | 741 | 18.8 | 1260 | 20.0 | 0.94 (0.87–1.02) | 0.89 (0.76–1.04) |
Duloxetine | 1249 | 7.5 | 2424 | 8.7 | 0.87 (0.81–0.93) | 0 | 0 | 348 | 8.8 | 607 | 9.6 | 0.92 (0.81–1.04) | ||||
NaSSA | 4882 | 29.5 | 7138 | 25.6 | 1.15 (1.12–1.19) | 429 | 28.1 | 797 | 27.8 | 1.01 (0.91–1.11) | 1046 | 26.6 | 1359 | 21.6 | 1.23 (1.15–1.32) | 1.22 (1.08–1.38) |
Mirtazapine | 4809 | 29.1 | 7005 | 25.1 | 1.16 (1.12–1.19) | 400 | 26.2 | 751 | 26.2 | 1.00 (0.90–1.10) | 1042 | 26.5 | 1347 | 21.4 | 1.24 (1.15–1.33) | 1.24 (1.09–1.41) |
TCA | 2081 | 12.6 | 4006 | 14.4 | 0.87 (0.83–0.91) | 355 | 23.2 | 738 | 25.8 | 0.90 (0.81–1.01) | 327 | 8.3 | 561 | 8.9 | 0.93 (0.82–1.06) | 1.04 (0.87–1.23) |
Trimipramine | 647 | 3.9 | 1275 | 4.6 | 0.85 (0.80–0.94) | 109 | 7.1 | 218 | 7.6 | 0.94 (0.75–1.17) | 106 | 2.7 | 170 | 2.7 | 1.00 (0.79–1.27) | 1.07 (0.77–1.48) |
Amitriptyline | 627 | 3.8 | 1100 | 3.9 | 0.96 (0.87–1.06) | 78 | 5.1 | 141 | 4.9 | 1.04 (0.79–1.36) | 125 | 3.2 | 187 | 3.0 | 1.07 (0.86–1.34) | 1.03 (0.73–1.46) |
Doxepin | 390 | 2.4 | 776 | 2.8 | 0.84 (0.75–0.95) | 82 | 5.4 | 173 | 6.0 | 0.89 (0.67–1.15) | 55 | 1.4 | 109 | 1.7 | 0.81 (0.59–1.11) | 0.91 (0.60–1.37) |
MAOI | 236 | 1.4 | 369 | 1.3 | 1.08 (0.92–1.27) | 36 | 2.4 | 56 | 2.0 | 1.21 (0.80–1.82) | 48 | 1.2 | 69 | 1.1 | 1.11 (0.77–1.61) | 0.92 (0.53–1.61) |
Other ADDs | 2049 | 12.4 | 3590 | 12.9 | 0.96 (0.91–1.01) | 112 | 7.3 | 204 | 7.1 | 1.03 (0.82–1.29) | 661 | 16.8 | 1189 | 18.9 | 0.89 (0.82–0.97) | 0.86 (0.68–1.10) |
Trazodone | 879 | 5.3 | 1720 | 6.2 | 0.86 (0.80–0.93) | 33 | 2.2 | 51 | 1.8 | 1.21 (0.79–1.87) | 295 | 7.5 | 656 | 10.4 | 0.72 (0.63–0.82) | 0.59 (0.38–0.93) |
Bupropion | 578 | 3.5 | 647 | 2.3 | 1.50 (1.35–1.68) | 0 | 0 | 232 | 5.9 | 249 | 3.9 | 1.49 (1.25–1.78) | ||||
Agomelatine | 389 | 2.4 | 811 | 2.9 | 0.81 (0.72–0.91) | 0 | 0 | 105 | 2.7 | 232 | 3.7 | 0.72 (0.58–0.91) |
Antipsychotic drugs
2001–2017 | 2001–2003 | 2015–2017 | Sex differences over time | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | M vs. F | M | F | M vs. F | M | F | M vs. F | 2001–2003 vs. 2015–2017 | |||||||
N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | RRR (95% C1) | |
N patients | 16,547 | 27,871 | 1527 | 2863 | 3936 | 6304 | ||||||||||
APD | ||||||||||||||||
Any APD | 8162 | 49.3 | 13,761 | 49.4 | 1.00 (0.98–1.02) | 694 | 45.4 | 1250 | 43.7 | 1.04 (0.97–1.12) | 2028 | 51.5 | 3062 | 48.6 | 1.06 (1.02–1.10) | 1.02 (0.94–1.10) |
SGA | 6117 | 37.0 | 9742 | 35.0 | 1.06 (1.03–1.06) | 460 | 30.1 | 708 | 24.7 | 1.22 (1.10–1–35) | 1619 | 41.1 | 2360 | 37.4 | 1.10 (1.05–1.15) | 0.90 (0.81–1.01) |
Quetiapine | 2973 | 18.0 | 4815 | 17.3 | 1.04 (1.00–1.08) | 42 | 2.8 | 92 | 3.2 | 0.86 (0.60–1.23) | 906 | 23.0 | 1313 | 20.8 | 1.11 (1.03–1.19) | 1.29 (0.89–1.86) |
Olanzapine | 1544 | 9.3 | 2238 | 8.0 | 1.16 (1.09–1.24) | 219 | 14.3 | 302 | 10.5 | 1.36 (1.16–1.60) | 313 | 8.0 | 416 | 6.6 | 1.21 (1.05–1.39) | 0.89 (0.71–1.10) |
Risperidone | 1107 | 6.7 | 1727 | 6.2 | 1.09 (1.01–1.17) | 130 | 8.5 | 206 | 7.2 | 1.18 (0.96–1.46) | 284 | 7.2 | 424 | 6.7 | 1.07 (0.93–1.24) | 0.91 (0.70–1.17) |
Aripiprazol | 397 | 2.4 | 746 | 2.7 | 0.90 (0.79–1.01) | 0 | 0 | 166 | 4.2 | 297 | 4.7 | 0.90 (0.74–1.08) | ||||
FGA lp | 2714 | 16.4 | 5271 | 18.9 | 0.86 (0.83–0.90) | 233 | 15.3 | 535 | 18.7 | 0.82 (0.71–0.94) | 594 | 15.1 | 1079 | 17.1 | 0.88 (0.80–0.97) | 1.08 (0.91–1.28) |
Pipamperone | 779 | 4.7 | 1474 | 5.3 | 0.89 (0.82–0.97) | 45 | 2.9 | 113 | 3.9 | 0.75 (0.53–1.05) | 223 | 5.7 | 386 | 6.1 | 0.93 (0.79–1.09) | 1.24 (0.85–1.80) |
Promethazine | 552 | 3.3 | 1158 | 4.2 | 0.80 (0.73–0.87) | 48 | 3.1 | 125 | 4.4 | 0.72 (0.52–1.00) | 104 | 2.6 | 239 | 3.8 | 0.70 (0.56–0.87) | 0.97 (0.65–1.44) |
Prothipendyl | 599 | 3.6 | 1109 | 4.0 | 0.91 (0.83–1.00) | 42 | 2.8 | 85 | 3.0 | 0.93 (0.64–1.33) | 157 | 4.0 | 268 | 4.3 | 0.95 (0.77–1.14) | 1.01 (0.67–1.53) |
Melperone | 357 | 2.2 | 848 | 3.0 | 0.71 (0.63–0.80) | 38 | 2.5 | 111 | 3.9 | 0.64 (0.25–0.92) | 55 | 1.4 | 104 | 1.6 | 0.85 (0.61–1.17) | 1.32 (0.81–2.15) |
FGA hp | 499 | 3.0 | 911 | 3.3 | 0.92 (0.83–1.03) | 114 | 7.5 | 189 | 6.6 | 1.13 (0.90–1.41) | 62 | 1.6 | 108 | 1.7 | 0.92 (0.67–1.25) | 0.81 (0.55–1.19) |
Tranquilizing and hypnotic drugs
2001–2017 | 2001–2003 | 2015–2017 | Sex differences over time | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | M vs. F | M | F | M vs. F | M | F | M vs. F | 2001–2003 vs. 2015–2017 | |||||||
N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | RRR (95% C1) | |
N patients | 16,547 | 27,871 | 1527 | 2863 | 3936 | 6304 | ||||||||||
TRD | ||||||||||||||||
Any TRD | 4498 | 27.2 | 8497 | 30.5 | 0.89 (0.86–0.92) | 505 | 33.1 | 1019 | 35.6 | 0.93 (0.85–1.01) | 910 | 23.1 | 1623 | 25.7 | 0.90 (0.84–0.96) | 0.97 (0.86–1.08) |
Lorazepam | 3056 | 18.5 | 5575 | 20.0 | 0.92 (0.89–0.96) | 310 | 20.3 | 625 | 21.8 | 0.93 (0.82–1.05) | 629 | 16.0 | 1073 | 17.0 | 0.94 (0.86–1.03) | 1.01 (0.87–1.17) |
Diazepam | 534 | 3.2 | 944 | 3.4 | 0.95 (0.86–1.06) | 64 | 4.2 | 158 | 5.5 | 0.76 (0.57–1.01) | 72 | 1.8 | 92 | 1.5 | 1.25 (0.92–1.70) | 1.65 (1.06–2.50) |
Oxazepam | 419 | 2.5 | 868 | 3.1 | 0.81 (0.72–0.91) | 62 | 4.1 | 109 | 3.8 | 1.07 (0.79–1.45) | 93 | 2.4 | 187 | 3.0 | 0.80 (0.62–1.02) | 0.75 (0.50–1.11) |
HYPD | ||||||||||||||||
Any HYPD | 2266 | 13.7 | 4491 | 16.1 | 0.85 (0.81–0.89) | 338 | 22.1 | 672 | 23.5 | 0.94 (0.84–1.06) | 351 | 8.9 | 755 | 12.0 | 0.74 (0.66–0.84) | 0.79 (0.67–0.93) |
Zopiclone | 1080 | 6.5 | 2017 | 7.2 | 0.90 (0.84–0.97) | 95 | 6.2 | 204 | 7.1 | 0.87 (0.69–1.10) | 135 | 3.4 | 270 | 4.3 | 0.80 (0.65–0.98) | 0.92 (0.67–1.25) |
Zolpidem | 700 | 4.2 | 1415 | 5.1 | 0.83 (0.76–0.91) | 161 | 10.5 | 315 | 11.0 | 0.96 (0.80–1.17) | 119 | 3.0 | 233 | 3.7 | 0.82 (0.66–1.02) | 0.85 (0.64–1.13) |
AED | ||||||||||||||||
Any AED | 2348 | 14.2 | 4255 | 15.3 | 0.92 (0.88–0.97) | 205 | 13.4 | 337 | 11.8 | 1.14 (0.97–1.34) | 506 | 12.9 | 1011 | 16.0 | 0.80 (0.73–0.89) | 0.70 (0.58–0.85) |
Pregabalin | 751 | 4.5 | 1483 | 5.3 | 0.85 (0.78–0.93) | 0 | 0 | 240 | 6.1 | 532 | 8.4 | 0.72 (0.62–0.83) | ||||
Lamotrgine | 393 | 2.4 | 945 | 3.4 | 0.70 (0.62–0.79) | 20 | 1.3 | 37 | 1.3 | 1.0.1 (0.59–1.74) | 81 | 2.1 | 220 | 3.5 | 0.59 (0.45–0.76) | 0.58 (0.32–1.06) |
Valproic acid | 539 | 3.3 | 692 | 2.5 | 1.31 (1.17–1.47) | 51 | 3.3 | 90 | 3.1 | 1.06 (0.76–1.49) | 72 | 1.8 | 78 | 1.2 | 1.48 (1.08–2.03) | 1.39 (0.88–2.21) |
Lithium | ||||||||||||||||
Any LI salt | 969 | 5.9 | 1436 | 5.2 | 1.14 (1.05–1.23) | 136 | 8.9 | 214 | 7.5 | 1.19 (0.97–1.46) | 205 | 5.2 | 293 | 4.6 | 1.12 (0.94–1.33) | 0.94 (0.72–1.23) |
Antiepileptic drugs and lithium
Trends in polypsychopharmacy
2001–2017 | 2001–2003 | 2015–2017 | Sex differences over time | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | M vs. F | M | F | M vs. F | M | F | M vs. F | 2001–2003 vs. 2015–2017 | |||||||
N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | RRR (95% C1) | |
N patients | 16,547 | 27,871 | 1527 | 2863 | 3936 | 6304 | ||||||||||
Combination with any ADD (% of pat. treated with ADD) | ||||||||||||||||
N pat. with ADD | 14,431 | 24,794 | 1361 | 2578 | 3311 | 5445 | ||||||||||
ADD + | ||||||||||||||||
ADD | 4614 | 32.0 | 7717 | 31.1 | 1.03 (1.00–1.06) | 349 | 25.6 | 616 | 23.9 | 1.07 (0.96–1.20) | 1121 | 33.9 | 1765 | 32.4 | 1.04 (0.98–1.11) | 0.97 (0.86–1.11) |
APD | 7257 | 50.3 | 12433 | 50.1 | 1.00 (0.98–1.02) | 637 | 46.8 | 1138 | 44.1 | 1.06 (0.99–1.14) | 1753 | 52.9 | 2719 | 49.9 | 1.06 (1.02–1.11) | 1.00 (0.92–1.09) |
TRD | 4041 | 28.0 | 7683 | 31.0 | 0.90 (0.88–0.93) | 470 | 34.5 | 934 | 36.2 | 0.95 (0.87–1.04) | 792 | 23.9 | 1441 | 26.5 | 0.90 (0.84–0.97) | 0.95 (0.84–1.07) |
HYPD | 2056 | 14.2 | 4107 | 16.6 | 0.86 (0.82–0.90) | 309 | 22.7 | 612 | 23.7 | 0.96 (0.85–1.08) | 312 | 9.4 | 663 | 12.2 | 0.77 (0.68–0.88) | 0.81 (0.68–0.96) |
LI | 904 | 6.3 | 1325 | 5.3 | 1.17 (1.08–1.27) | 126 | 9.3 | 196 | 7.6 | 1.22 (0.98–1.51) | 195 | 5.9 | 276 | 5.1 | 1.16 (0.97–1.39) | 0.95 (0.72–1.26) |
AED | 2042 | 14.2 | 3825 | 15.4 | 0.91 (0.87–0.96) | 185 | 13.6 | 306 | 11.9 | 1.15 (0.97–1.36) | 433 | 13.1 | 909 | 16.7 | 0.78 (0.70–0.87) | 0.68 (0.56–0.84) |
Combination of ADD with (% of pat. treated with ADD) | ||||||||||||||||
ADD + | ||||||||||||||||
ADD + APD | 2356 | 16.3 | 3748 | 15.1 | 1.08 (1.03–1.13) | 158 | 11.6 | 265 | 10.3 | 1.13 (0.94–1.36) | 599 | 18.1 | 862 | 15.8 | 1.14 (1.04–1.26) | 1.01 (0.82–1.25) |
APD + APD | 1305 | 9.0 | 2422 | 9.8 | 0.93 (0.86–0.99) | 118 | 8.7 | 187 | 7.3 | 1.20 (0.96–1.49) | 296 | 8.9 | 593 | 10.9 | 0.82 (0.72–0.94) | 0.69 (0.53–0.89) |
APD + TRD | 2373 | 16.4 | 4465 | 18.0 | 0.91 (0.87–0.96) | 255 | 18.7 | 454 | 17.6 | 1.06 (0.93–1.22) | 486 | 14.7 | 860 | 15.8 | 0.93 (0.84–1.03) | 0.87 (0.74–1.04) |
APD + HYPD | 1119 | 7.8 | 2111 | 8.5 | 0.91 (0.85–0.98) | 143 | 10.5 | 253 | 9.8 | 1.07 (0.88–1.30) | 191 | 5.8 | 367 | 6.7 | 0.86 (0.72–1.01) | 0.80 (0.62–1.03) |
ADD and concomitant utilization of lp FGAs
2001–2017 | 2001–2003 | 2015–2017 | Sex differences over time | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | F | M vs. F | M | F | M vs. F | M | F | M vs. F | 2001–2003 vs. 2015–2017 | |||||||
N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | N | % | N | % | RR (95% CI) | RRR (95% C1) | |
N patients | 16547 | 27871 | 1527 | 2863 | 3936 | 6304 | ||||||||||
Combination with SSRI (% of pat. treated with SSRI) | ||||||||||||||||
N pat. with SSRI | 5154 | 8323 | 508 | 898 | 1199 | 2103 | ||||||||||
SSRI + | ||||||||||||||||
NaSSA | 1059 | 20.5 | 1599 | 19.2 | 1.07 (1.00–1.15) | 70 | 13.8 | 113 | 12.6 | 1.10 (0.83–1.45) | 238 | 19.8 | 330 | 15.7 | 1.27 (1.09–1.47) | 1.16 (0.84–1.58) |
SGA | 1838 | 35.7 | 2937 | 35.3 | 1.01 (0.96–1.06) | 167 | 32.9 | 207 | 23.1 | 1.43 (1.20–1.69) | 498 | 41.5 | 727 | 34.6 | 1.20 (1.10–1.31) | 0.84 (0.69–1.02) |
lp FGA | 846 | 16.4 | 1682 | 20.2 | 0.81 (0.75–0.88) | 77 | 15.2 | 158 | 17.6 | 0.86 (0.67–1.11) | 180 | 15.0 | 315 | 15.0 | 1.00 (0.85–1.19) | 1.16 (0.86–1.57) |
TRD | 1334 | 25.9 | 2640 | 31.7 | 0.82 (0.77–0.86) | 148 | 29.1 | 288 | 32.1 | 0.91 (0.77–1.07) | 275 | 22.9 | 534 | 25.4 | 0.90 (0.80–1.03) | 0.99 (0.81–1.23) |
HYPD | 680 | 13.2 | 1403 | 16.9 | 0.78 (0.72–0.85) | 105 | 20.7 | 193 | 21.5 | 0.96 (0.78–1.19) | 91 | 7.6 | 232 | 11.0 | 0.69 (0.55–0.87) | 0.72 (0.52–0.98) |
Combination with SSNRI (% of pat. treated with SSNRI) | ||||||||||||||||
N pat. with SSNRI | 4689 | 9208 | 277 | 494 | 1150 | 1947 | ||||||||||
SSNRI + | ||||||||||||||||
NaSSA | 1268 | 27.0 | 1825 | 19.8 | 1.36 (1.28–1.45) | 69 | 24.9 | 97 | 19.6 | 1.27 (0.97–1.66) | 325 | 28.3 | 406 | 20.9 | 1.36 (1.19–1.53) | 1.07 (0.79–1.44) |
SGA | 2099 | 44.8 | 3521 | 38.2 | 1.17 (1.12–1.22) | 106 | 38.3 | 147 | 29.8 | 1.29 (1.05–1.57) | 548 | 47.7 | 874 | 44.9 | 1.06 (0.98–1.15) | 0.83 (0.66–1.02) |
lp FGA | 830 | 17.7 | 1780 | 19.3 | 0.92 (0.85–0.99) | 43 | 15.5 | 104 | 21.1 | 0.73 (0.53–1.02) | 191 | 16.6 | 400 | 20.5 | 0.81 (0.69–0.95) | 1.10 (0.77–1.57) |
TRD | 1367 | 29.2 | 2653 | 28.8 | 1.01 (0.96–1.07) | 124 | 44.8 | 211 | 42.7 | 1.05 (0.89–1.24) | 289 | 25.1 | 533 | 27.4 | 0.92 (0.81–1.04) | 0.88 (0.71–1.08) |
HYPD | 666 | 14.2 | 1375 | 14.9 | 0.95 (0.87–1.04) | 61 | 22.0 | 110 | 22.3 | 0.99 (0.75–1.30) | 111 | 9.7 | 251 | 12.9 | 0.75 (0.61–0.92) | 0.76 (0.53–1.07) |
Combination with NaSSA (% of pat. treated with NaSSA) | ||||||||||||||||
N pat. with NaSSA | 4882 | 7138 | 429 | 797 | 1046 | 1359 | ||||||||||
NaSSA + | ||||||||||||||||
SGA | 1708 | 35.0 | 2388 | 33.5 | 1.05 (0.99–1.10) | 118 | 27.5 | 188 | 23.6 | 1.17 (0.96–1.42) | 416 | 39.8 | 501 | 36.9 | 1.08 (0.97–1.19) | 0.93 (0.74–1.16) |
lp FGA | 771 | 15.8 | 1287 | 18.0 | 0.88 (0.81–0.95) | 60 | 14.0 | 170 | 21.3 | 0.66 (0.50–0.86) | 165 | 15.8 | 204 | 15.0 | 1.05 (0.87–1.27) | 1.60 (1.15–2.23) |
TRD | 1547 | 31.7 | 2483 | 34.8 | 0.91 (0.86–0.96) | 162 | 37.8 | 330 | 41.4 | 0.91 (0.79–1.06) | 295 | 28.2 | 407 | 29.9 | 0.94 (0.83–1.07) | 1.03 (0.85–1.25) |
HYPD | 670 | 13.7 | 1388 | 19.4 | 0.71 (0.65–0.77) | 101 | 23.5 | 207 | 26.0 | 0.91 (0.74–1.11) | 103 | 9.8 | 175 | 12.9 | 0.76 (0.61–0.96) | 0.84 (0.62–1.15) |